Oral fluticasone propionate in active distal ulcerative colitis.

Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease

“…55 Another trial with¯uticasone was performed in patients with active distal UC. 61 The conclusion of this study was that after 4 weeks of therapy,¯uticasone propionate (5 mg four times daily) was ineffective in controlling active distal disease. Again, the dosage form in this placebocontrolled study was not a colon targeted preparation.…”

“…It was hoped that relatively large amounts of the drug would reach the colon and eventually be excreted in the faeces, and that a colonic delivery system was unnecessary 55 . Another trial with fluticasone was performed in patients with active distal UC 61 . The conclusion of this study was that after 4 weeks of therapy, fluticasone propionate (5 mg four times daily) was ineffective in controlling active distal disease.…”

“…58 The anti-in¯ammatory effect of¯uticasone propionate has been examined in both Crohn's disease 59 and UC. 60,61 In the evaluation of Crohn's disease,¯uticasone (20 mg/day orally in four divided doses over 3 weeks) signi®cantly reduced disease activity without any signi®cant changes in plasma cortisol levels. However, this study was uncontrolled, and as a result the most meaningful parameter measured was the cortisol levels.…”

Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials

“…In 1 trial, patients with mildly to moderately active L-UC were randomized to receive placebo or fluticasone propionate 5 mg tablets 4 times daily for 4 weeks. 40 At the conclusion of therapy, clinical, sigmoidoscopic and histological parameters were similar between groups; the In this double-blind, controlled trial, 72 patients with mildly to moderately active extensive and L-UC were randomized to receive either budesonide 10 mg or prednisolone 40 mg daily. Both were gradually tapered, and endoscopic improvement and plasma cortisol levels were assessed.…”

“…Few randomized, placebo‐controlled trials of orally administered, topically active corticosteroids have been performed in L‐UC (Table 1). In 1 trial, patients with mildly to moderately active L‐UC were randomized to receive placebo or fluticasone propionate 5 mg tablets 4 times daily for 4 weeks 40. At the conclusion of therapy, clinical, sigmoidoscopic and histological parameters were similar between groups; the authors concluded that fluticasone was ineffective in active UC.…”